Skip to main content
TipRanks
Go Ultimate75% OFF

TME Pharma N.V. (0N6A) AI Stock Analysis

1 Followers
DE:0N6A

TME Pharma N.V.

(Frankfurt:0N6A)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Focused oncology pipelineA focused oncology pipeline gives TME Pharma a clear strategic identity and concentrates resources on diseases with substantial unmet need. Progress in clinical development could create durable value through differentiated treatment options, although outcomes remain dependent on successful execution and trial results.
Negative Factors
Pre-commercial revenue profileNear-zero revenue means the business has not yet established a commercial earnings base and remains dependent on development milestones rather than recurring product sales. The return to zero revenue in 2025 underscores limited near-term revenue visibility and a long path to self-funded operations.

TME Pharma N.V. (0N6A) vs. iShares MSCI Germany ETF (EWG)

-50%0%50%100%150%200%DE:0N6A+68.85%EWG+6.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 9.76M
Dividend Yield
―
Average Volume (3M)
78.12K
Price to Earnings (P/E)
-5.6
Beta (1Y)
-0.12
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
12
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

TME Pharma N.V. Business Overview & Revenue Model

Company Description

TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipelin...

TME Pharma N.V. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:0N6A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:IPHFR:IPH50NeutralEUR 110.36M-1.94152.56%―-29.48%7.91%
FR:ALCLSFR:ALCLS46NeutralEUR 71.53M-0.85-319.92%―-5.98%-8.67%
FR:TNGFR:TNG46NeutralEUR 194.24M-4.18-29.36%―189.81%38.50%
FR:NANOFR:NANO44NeutralEUR 1.26B-21.8989.71%―――
FR:OSEFR:OSE37UnderperformEUR 34.33M-0.86-96.73%―-96.25%-197.89%

* Healthcare Sector Average

Performance Comparison

0%100%DE:0N6AFR:IPHFR:NANOFR:TNGFR:OSEFR:ALCLSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:0N6A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:0N6ATME Pharma N.V.0.100.0463.49%
FR:IPHInnate Pharma S.A.0.99-0.63-39.01%
FR:NANONanobiotix SA24.085.8832.31%
FR:TNGTransgene SA0.70-0.56-44.60%
FR:OSEOSE Immunotherapeutics1.46-3.90-72.75%
FR:ALCLSCellectis SA0.99-3.12-75.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.